Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort.

IF 7.9 1区 医学 Q1 CLINICAL NEUROLOGY Alzheimer's Research & Therapy Pub Date : 2024-11-28 DOI:10.1186/s13195-024-01622-5
Matteo Tonietto, Oscar Sotolongo-Grau, Núria Roé-Vellvé, Santiago Bullich, Juan Pablo Tartari, Ángela Sanabria, Ainhoa García-Sánchez, Edilio Borroni, Christopher Galli, Esther Pérez-Martínez, Joan Castell-Conesa, Isabel Roca, Lluís Tárraga, Agustín Ruiz, Andrew W Stephens, Mercè Boada, Gregory Klein, Marta Marquié
{"title":"Head-to-head comparison of tau PET tracers [<sup>18</sup>F]PI-2620 and [<sup>18</sup>F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort.","authors":"Matteo Tonietto, Oscar Sotolongo-Grau, Núria Roé-Vellvé, Santiago Bullich, Juan Pablo Tartari, Ángela Sanabria, Ainhoa García-Sánchez, Edilio Borroni, Christopher Galli, Esther Pérez-Martínez, Joan Castell-Conesa, Isabel Roca, Lluís Tárraga, Agustín Ruiz, Andrew W Stephens, Mercè Boada, Gregory Klein, Marta Marquié","doi":"10.1186/s13195-024-01622-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Second-generation tau tracers for positron emission tomography (PET) show high affinity for paired helical filaments tau deposits characteristic of Alzheimer´s disease and low off-target binding. Differences in their chemical structure though may lead to variations in their regional tau uptake and off-target signal. In this work, we aimed to compare the in-vivo uptake of tau tracers [<sup>18</sup>F]PI-2620 and [<sup>18</sup>F]RO948 in the early stages of the AD continuum.</p><p><strong>Methods: </strong>Data from the TAU-PET FACEHBI clinical trial (EUDRA-CT 2021-000473-83) were analyzed. All participants were non-demented and underwent tau imaging with [<sup>18</sup>F]PI-2620 and [<sup>18</sup>F]RO948 PET within 3 months, amyloid imaging with [<sup>18</sup>F]Florbetaben and brain magnetic resonance imaging. Tau PET standardized uptake values ratios (SUVR) were calculated in Braak and typical off-target regions using the inferior cerebellar cortex as a reference region.</p><p><strong>Results: </strong>The cohort consisted of 18 individuals with subjective cognitive decline (n = 13) and mild cognitive impairment (n = 5), with centiloid values ranging from 17 to 159. Both tau tracers showed similar tau pathology distribution but presented a distinct off-target signal pattern on visual read. SUVR measurements for [<sup>18</sup>F]PI-2620 and [<sup>18</sup>F]RO948 were highly correlated in all Braak regions (R<sup>2</sup> range [0.65-0.80]). Regarding off-target signal, [<sup>18</sup>F]PI-2620 had higher SUVRs in vascular structures, and [<sup>18</sup>F]RO948 had higher SUVRs in the skull/meninges.</p><p><strong>Conclusions: </strong>In a cohort of individuals at early stages of the AD continuum, tau PET tracers [<sup>18</sup>F]PI-2620 and [<sup>18</sup>F]RO948 showed similar in-vivo uptake in all Braak regions and distinct off-target signal. These preliminary results support the development of standardized quantification scales for tau deposition that are tracer-independent.</p><p><strong>Trial registration: </strong>AEMPS EudraCT 2021-000473-83. Registered 30 December 2021.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"257"},"PeriodicalIF":7.9000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11603960/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-024-01622-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Second-generation tau tracers for positron emission tomography (PET) show high affinity for paired helical filaments tau deposits characteristic of Alzheimer´s disease and low off-target binding. Differences in their chemical structure though may lead to variations in their regional tau uptake and off-target signal. In this work, we aimed to compare the in-vivo uptake of tau tracers [18F]PI-2620 and [18F]RO948 in the early stages of the AD continuum.

Methods: Data from the TAU-PET FACEHBI clinical trial (EUDRA-CT 2021-000473-83) were analyzed. All participants were non-demented and underwent tau imaging with [18F]PI-2620 and [18F]RO948 PET within 3 months, amyloid imaging with [18F]Florbetaben and brain magnetic resonance imaging. Tau PET standardized uptake values ratios (SUVR) were calculated in Braak and typical off-target regions using the inferior cerebellar cortex as a reference region.

Results: The cohort consisted of 18 individuals with subjective cognitive decline (n = 13) and mild cognitive impairment (n = 5), with centiloid values ranging from 17 to 159. Both tau tracers showed similar tau pathology distribution but presented a distinct off-target signal pattern on visual read. SUVR measurements for [18F]PI-2620 and [18F]RO948 were highly correlated in all Braak regions (R2 range [0.65-0.80]). Regarding off-target signal, [18F]PI-2620 had higher SUVRs in vascular structures, and [18F]RO948 had higher SUVRs in the skull/meninges.

Conclusions: In a cohort of individuals at early stages of the AD continuum, tau PET tracers [18F]PI-2620 and [18F]RO948 showed similar in-vivo uptake in all Braak regions and distinct off-target signal. These preliminary results support the development of standardized quantification scales for tau deposition that are tracer-independent.

Trial registration: AEMPS EudraCT 2021-000473-83. Registered 30 December 2021.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在有脑淀粉样蛋白沉积的非痴呆症患者中对tau PET示踪剂[18F]PI-2620和[18F]RO948进行头对头比较:TAU-PET FACEHBI队列。
背景:用于正电子发射断层扫描(PET)的第二代 tau 示踪剂对阿尔茨海默病特有的成对螺旋丝 tau 沉积物具有高亲和力,而脱靶结合率低。不过,它们化学结构的差异可能会导致其区域性 tau 吸收和脱靶信号的不同。在这项工作中,我们旨在比较tau示踪剂[18F]PI-2620和[18F]RO948在AD早期阶段的体内摄取情况:分析了TAU-PET FACEHBI临床试验(EUDRA-CT 2021-000473-83)的数据。所有参与者均未痴呆,并在3个月内接受了[18F]PI-2620和[18F]RO948 PET的tau成像、[18F]Florbetaben的淀粉样蛋白成像和脑磁共振成像。以小脑下皮层为参照区域,计算布拉克和典型脱靶区域的 Tau PET 标准化摄取值比(SUVR):研究对象包括18名主观认知能力下降患者(13人)和轻度认知障碍患者(5人),中心值从17到159不等。两种tau示踪剂显示出相似的tau病理分布,但在视觉读数上呈现出明显的脱靶信号模式。[18F]PI-2620和[18F]RO948的SUVR测量值在所有Braak区域都高度相关(R2范围为[0.65-0.80])。关于脱靶信号,[18F]PI-2620在血管结构中的SUVR较高,而[18F]RO948在颅骨/脑膜中的SUVR较高:结论:在一组处于AD早期阶段的个体中,tau PET示踪剂[18F]PI-2620和[18F]RO948在所有Braak区域显示出相似的体内摄取和不同的脱靶信号。这些初步结果支持开发与示踪剂无关的tau沉积标准化量化标度:试验注册:AEMPS EudraCT 2021-000473-83。注册日期:2021 年 12 月 30 日。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Alzheimer's Research & Therapy
Alzheimer's Research & Therapy 医学-神经病学
CiteScore
13.10
自引率
3.30%
发文量
172
审稿时长
>12 weeks
期刊介绍: Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.
期刊最新文献
β-synuclein in cerebrospinal fluid as a potential biomarker for distinguishing human prion diseases from Alzheimer's and Parkinson's disease. Heterogeneous clinical phenotypes of sporadic early-onset Alzheimer's disease: a neuropsychological data-driven approach. A systematic review and meta-analysis of the impact of transcranial direct current stimulation on cognitive function in older adults with cognitive impairments: the influence of dosage parameters. Delta-opioid receptor signaling alleviates neuropathology and cognitive impairment in the mouse model of Alzheimer's disease by regulating microglia homeostasis and inhibiting HMGB1 pathway. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: the need for rigor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1